文献速递妇科生殖医学

循环微小RNA miR-142-3p与miR-598-3p在多囊卵巢综合征女性中作为潜在诊断标志物的验证

Validation of circulating microRNAs miR-142-3p and miR-598-3p in women with polycystic ovary syndrome as potential diagnostic markers.
PubMed 文献 · Hum Reprod · 2023-01-01

这项诊断试验纳入140名绝经前女性(71例多囊卵巢综合征患者和69例健康对照),评估循环miR-142-3p与miR-598-3p的诊断准确性。两标志物联合的受试者工作特征曲线下面积为0.801(95%CI:0.72-0.88),加入腰臀比后为0.834(95%CI:0.756-0.912),加入促黄体生成素/促卵泡激素比值后为0.869(95%CI:0.804-0.934),同时加入两者后为0.895(95%CI:0.835-0.954)。

要点

  • 循环miR-142-3p与miR-598-3p联合诊断多囊卵巢综合征的AUC为0.801(95%CI:0.72-0.88)。
  • 加入腰臀比或促黄体生成素/促卵泡激素比值可提高诊断准确性,AUC分别达0.834和0.869。
  • 同时加入腰臀比和促黄体生成素/促卵泡激素比值时AUC为0.895(95%CI:0.835-0.954)。

核心结论

  • 基于循环miR-142-3p与miR-598-3p表达的模型在患与未患多囊卵巢综合征的女性之间显示出良好区分度。
  • 若在针对不同人群和多囊卵巢综合征表型的大型研究中得到证实,这些生物标志物可能有助于简化该 prevalent 综合征的临床诊断。

研究设计与样本

  • 诊断试验研究,纳入140名绝经前女性,其中多囊卵巢综合征患者71例、健康对照女性69例,两组体重指数相近。
  • 采用miRCURY LNA™ Universal RT microRNA PCR分析此前小型预试验中与多囊卵巢综合征关联最强的五种微小RNA,并通过受试者工作特征曲线分析评估诊断准确性。

主要发现

  • 所研究的五种微小RNA中,仅miR-142-3p与miR-598-3p在多囊卵巢综合征女性与非高雄激素对照女性之间表达不同。
  • 两种循环微小RNA联合的AUC为0.801(95%CI:0.72-0.88)。
  • 联合模型加入腰臀比后AUC为0.834(95%CI:0.756-0.912),加入促黄体生成素/促卵泡激素比值后AUC为0.869(95%CI:0.804-0.934),同时加入两者后AUC为0.895(95%CI:0.835-0.954)。
  • 通过选择偏向敏感性或特异性的不同阈值构建了多个模型,阳性预测值和阴性预测值分别高达88%和85%。

临床怎么用

  • 作者认为,若在针对不同人群和多囊卵巢综合征表型的大型研究中得到证实,这些生物标志物可能有助于简化该 prevalent 综合征的临床诊断。

局限性

  • 纳入的患者具有经典多囊卵巢综合征表型,即高雄激素症和排卵功能障碍,因此目前结果可能不适用于缺乏雄激素过多的较轻表型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Circulating miRNAs previously associated with androgen excess in women might be used as diagnostic biomarkers for polycystic ovary syndrome (PCOS). SUMMARY ANSWER: Models based on circulating miR-142-3p and miR-598-3p expression show good discrimination among women with and without PCOS, particularly when coupled with easily available measurements such as waist-to-hip ratio (WHR) and circulating LH-to-FSH (LH/FSH) ratios. WHAT IS KNOWN ALREADY: The lack of standardization of the signs, methods, and threshold values used to establish the presence of the diagnostic criteria (hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology) complicates the diagnosis of PCOS. Certain biomarkers may help with such a diagnosis. We conducted a validation study to check the diagnostic accuracy for PCOS of several miRNAs that were associated with the syndrome in a small pilot study that had been previously carried out by our research group. STUDY DESIGN, SIZE, DURATION: This was a diagnostic test study involving 140 premenopausal women. PARTICIPANTS/MATERIALS, SETTING, METHODS: We included 71 women with PCOS and 69 healthy control women in the study. Both groups were selected as to be similar in terms of body mass index. We used miRCURY LNA™ Universal RT microRNA PCR to analyse the five miRNAs that had shown the strongest associations with PCOS in a much smaller pilot study previously conducted by our group. We studied diagnostic accuracy using receiver operating characteristics (ROC) curve analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Only the expression of two miRNAs, miR-142-3p and miR-598-3p, of the five studied, was different between the women with PCOS and the non-hyperandrogenic controls. The diagnostic accuracy of the combination of these circulating miRNAs was good (area under the ROC curve (AUC) 0.801; 95% CI: 0.72-0.88) and was further improved when adding WHR (AUC 0.834, 95% CI: 0.756-0.912), LH/FSH ratio (AUC = 0.869, 95% CI: 0.804-0.934) or both (AUC = 0.895, 95% CI: 0.835-0.954). We developed several models by selecting different threshold values for these variables favouring either sensitivity or specificity, with positive and negative predictive values as high as 88% or 85%, respectively. LIMITATIONS, REASONS FOR CAUTION: Patients included here had the classic PCOS phenotype, consisting of hyperandrogenism and ovulatory dysfunction; hence, the present results might not apply to milder phenotypes lacking androgen excess. WIDER IMPLICATIONS OF THE FINDINGS: If confirmed in larger studies addressing different populations and PCOS phenotypes, these biomarkers may be useful to simplify the clinical diagnosis of this prevalent syndrome. STUDY FUNDING/COMPETING INTEREST(S): This research was funded by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (grants PI15/01686, PIE16/00050, PI18/01122 & PI21/00116) and co-funded by European Regional Development Fund 'A way to make Europe'. Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) are also initiatives of the Instituto de Salud Carlos III. The authors have no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Insenser M, Quintero A, de Lope S, et al. Validation of circulating microRNAs miR-142-3p and miR-598-3p in women with polycystic ovary syndrome as potential diagnostic markers. Hum Reprod. 2023. PMID: 36931262. doi:10.1093/humrep/dead043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。